Risk charts - Very popular but useless?

Vasa - Journal of Vascular Diseases

Volumn 39, Issue 4, 2010, Pages 287-289

  Sinzinger, Helmut ^a   Derfler, K ^b   Laimer, H ^c   Seyfried, H ^a   Maier, M ^b  

^a Institute for Diagnosis and Treatment of Lipid Disorders and Atherosclerosis (ATHOS)   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Center for Cardiac Rehabilitation   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

ATHEROSCLEROSIS; EDITORIAL; FAMILY HISTORY; HEALTH BEHAVIOR; HUMAN; LIFESTYLE; PHYSICAL ACTIVITY; RISK ASSESSMENT; SMOKING; SOCIAL BEHAVIOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HEALTH STATUS INDICATORS; HUMANS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS;

EID: 78649819088     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000050     Document Type: Editorial

References (13)

1. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003; 41: 1475-9.
2. Brabec E, Weiss K, Mayer K, Widhalm K, Sinzinger H. Atherosklerose- Risikofaktoren-Interventionsstudie-Innermanzing (ARII). Herz/Kreislauf. 1990; 4: 114-8.
3. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003; 327: 1267-72.
4. Cooper JA, Miller GH, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005; 181: 93-100.
5. Empana JP, Ducimetière P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003; 24: 1903-11.
6. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, Hunink MG. Systemic review of guidelines on cardiovascular risk assessment. Which recommendations should clinicians follow for a cardiovascular check? Arch Int Med 2010; 170: 27-40.
7. Hense HW, Schulte H, Löwel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937-45.
8. Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition survey. Am Heart J 2005; 150: 595-601.
9. Marrugat J, D'Agostini R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease function to European Mediterranean areas. J Epidemiol Community Health. 2003; 57: 634-8.
10. Sattlberger CM. Sind massenstrategische Risikokalkulationen für die Individualstrategie in Österreich anwendbar? Thesis, Medical University of Vienna, Austria 2008.
11. Silberbauer K, Sinzinger H. Vernünftiger Umgang mit Medikamenten. Blutfette. Hauptverband d. österr. Sozialversicherungsträger. Initiative Arznei und Vernunft 1999.
12. 2) in 50 patients with myocardial infarction at young age. Prostagl and Med 1981; 7: 125-32.
13. Uthoff H, Staub D, Socrates T, Meyerhans A, Bundi B, Schmid HP, Frauchiger, B. PROCAM-, FRAMINGHAM-, SCORE- and SMART - risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis. Vasa 2010; 39: 325-33.